Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Bioconjug Chem. 2019 Apr 19;30(5):1434–1441. doi: 10.1021/acs.bioconjchem.9b00178

Figure 5.

Figure 5.

Quantification of tracer biodistribution. (A) Uptake of 89Zr–Df–atezolizumab in H460 tumors as determined through region-of-interest analysis of PET images. (B) Tumor-to-muscle ratios for all studied H460 groups over time. Both analyses indicate the highest accumulation of 89Zr–Df–atezolizumab in the fractionated radiotherapy group. (C) Tumor uptake over time in H460 and A549 tumor xenografts receiving 2 Gy × 5 Fx. (D) Ex vivo biodistribution study results in the two tumor models at 96 h postinjection of tracers. *p < 0.05; **p < 0.01; n = 3–5.